In vivo therapeutic responses contingent on fanconi anemia/BRCA2 status of the tumor

Clinical Cancer Research

Volumn 11, Issue 20, 2005, Pages 7508-7515

  Van Der Heijden, Michiel S ^a,b   Brody, Jonathan R ^a   Dezentje, David A ^a   Gallmeier, Eike ^a   Cunningham, Steven C ^a   Swartz, Michael J ^a   DeMarzo, Angelo M ^a   Offerhaus, G Johan A ^b   Isacoff, William H ^c   Hruban, Ralph H ^a   Kern, Scott E ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; MELPHALAN; MITOMYCIN C; PACLITAXEL; VINBLASTINE;

ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE; CONTROLLED STUDY; CROSS LINKING; FANCONI ANEMIA; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRCA2 PROTEIN; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CHLORAMBUCIL; CISPLATIN; CROSS-LINKING REAGENTS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ETOPOSIDE; FANCONI ANEMIA COMPLEMENTATION GROUP C PROTEIN; FANCONI ANEMIA COMPLEMENTATION GROUP G PROTEIN; FANCONI ANEMIA COMPLEMENTATION GROUP PROTEINS; FEMALE; FLUOROURACIL; HUMANS; INHIBITORY CONCENTRATION 50; MELPHALAN; MICE; MICE, NUDE; MITOMYCIN; MUTATION; PACLITAXEL; PANCREATIC NEOPLASMS; TIME FACTORS; VINBLASTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 27144532118     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1048     Document Type: Article

References (27)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
3. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-10.
4. Sadoff L, Latino F. Complete clinical remission in a patient with advanced pancreatic cancer using mitomycin C-based chemotherapy: the role of adjunctive heparin. Am J Clin Oncol 1999;22:187-90.
5. Takada T, Nimura Y, Katoh H, et al. Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial. Hepatogastroenterology 1998;45:2020-6.
6. Todd KE, Gloor B, Lane JS, lsacoff WH, Reber HA. Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole. J Gastrointest Surg 1998;2:159-66.
7. Slater S, Shamash J, Wilson P, Gallagher CJ, Slevin ML. Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers-a new active regimen. Br J Cancer 2002;87:850-3.
8. Petty RD, Nicolson MC, Skaria S, Sinclair TS, Samuel LM, Koruth MA. phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity. Ann Oncol 2003;14:1100-5.
9. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
10. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
11. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
12. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
13. Goggins M, Schutte M, Lu J, et al. Germ line BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56:5360-4.
14. Van Der Heijden MS, Brody JR, Gallmeier E, et al. Functional defects in the fanconi anemia pathway in pancreatic cancer cells. Am J Pathol 2004;165:651-7.
15. Van der Heijden MS,Yeo CJ, Hruban RH, Kern SE. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 2003;63:2585-8.
16. Couch FJ, Johnson MR, Rabe K, et al. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res 2005;65:383-6.
17. Garcia-Higuera I, D'Andrea AD. Nuclear localization of the Fanconi anemia protein FANCC is required for functional activity. Blood 1999;93:4025-6.
18. Kuang Y, Garcia-Higuera I, Moran A, Mondoux M, Digweed M, D'Andrea AD. Carboxy terminal region of the Fanconi anemia protein, FANCG/XRCC9, is required for functional activity. Blood 2000;96:1625-32.
19. Faith DA, Isaacs WB, Morgan JD, et al. Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. Prostate 2004;61:215-27.
20. Akkari YM, Bateman RL, Reifsteck CA, D'Andrea AD, Olson SB, Grompe M. The 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase. Mol Genet Metab 2001;74:403-12.
21. 2/M arrest in group C Fanconi anemia lymphoblasts reflects normal checkpoint function. Blood 1998;91:275-87.
22. Van der Heijden MS, Kern SE. Cancer-associated genes. In: Von Hoff DD, Evans DB, Hruban RH, editors. Pancreatic cancer. Sudbury: Jones and Bartlett; 2005. p. 31 -40.
23. Auerbach AD, Wolman SR. Susceptibility of Fanconi's anaemia fibroblasts to chromosome damage by carcinogens. Nature 1976;261:494-6.
24. Wilson JB, Johnson MA, Stuckert AP, et al. The Chinese hamster FANCG/XRCC9 mutant NM3 fails to express the monoubiquitinated form of the FANCD2 protein, is hypersensitive to a range of DNA damaging agents and exhibits a normal level of spontaneous sister chromatid exchange. Carcinogenesis 2001;22:1939-46.
25. Ishida R, Buchwald M. Susceptibility of Fanconi's anemia lymphoblasts to DNA-cross-linking and alkylating agents. Cancer Res 1982;42:4000-6.
26. Busch DB, Zdzienicka MZ, Natarajan AT, et al. A CHO mutant, UV40, that is sensitive to diverse mutagens and represents a new complementation group of mitomycin C sensitivity. Mutat Res 1996;363:209-21.
27. Louvet C, Andre T, Lledo G, et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 2002;20:1512-8.